GIP

GIP belongs on this site because it is the parent hormone of the GIP arm of the modern dual-agonist class — the mechanistic innovation that distinguishes tirzepatide from the GLP-1 monoagonists (semaglutide, liraglutide, exenatide) and that, together with the glucagon-receptor arm, defines retatrutide and the experimental GIPR / GCGR co-agonist pharmacology behind it. The native hormone itself is a research tool. The clinical story belongs to the engineered analogs on the receptor.

The discovery story is older than GLP-1's. GIP was the first incretin characterized — the hormone whose existence anchored the modern "enteroinsular axis" concept of nutrient-stimulated insulin secretion. John Brown and Raymond Pederson at the University of British Columbia, working with Viktor Mutt at the Karolinska Institute, purified the peptide from porcine intestinal extracts across 1969–1971, reporting first an enterogastrone-active polypeptide that inhibited gastric acid secretion in dogs (Brown, Mutt and Pederson, J Physiol 1970, 209:57–64) and then the complete 42-residue porcine amino-acid sequence (Brown and Dryburgh, Can J Biochem 1971, 49:867–872). The original name — "gastric inhibitory polypeptide" — captured the acid-suppression effect that drove the purification work. The insulinotropic action was characterized five years later by Pederson and Brown in the perfused rat pancreas (Pederson and Brown 1976), demonstrating the strictly glucose-dependent stimulus-secretion coupling that established the molecule as the first incretin and ultimately motivated the renaming to "glucose-dependent insulinotropic polypeptide" while preserving the GIP acronym (Pederson, J Diabetes Investig 2016, 7 Suppl 1:4–7). GLP-1 was not characterized as a distinct insulinotropic hormone until the 1980s, after proglucagon was cloned and the tissue-specific post-translational processing of the prohormone in intestinal L-cells (which produce GLP-1) versus pancreatic α-cells (which produce glucagon) was worked out. GIP led; GLP-1 followed; for two decades GIP was the canonical incretin, and the modern dominance of GLP-1-class pharmacology in obesity and diabetes is a comparatively recent development.

A central paradox shaped the field for thirty years. The physiology of GIP, characterized across two decades of nutrient-clamp, infusion, and knockout work, was unambiguously lipid-storage-promoting in adipose tissue: GIPR-knockout mice on high-fat diets were leaner than wild-type controls and partially resistant to diet-induced obesity, and anti-GIPR monoclonal antibodies produced weight loss in obese rodents and non-human primates (Killion et al., Sci Transl Med 2018, 10(472):eaat3392). The Amgen anti-GIPR antibody program — and an adjacent body of academic work on GIPR antagonism — built a credible preclinical case that GIPR blockade, not activation, was the obesity-therapeutic direction. That hypothesis was the dominant frame across the GIP literature through approximately 2015, which made the pharmacological premise of tirzepatide — a GIP-receptor agonist component layered onto GLP-1 agonism — counter-intuitive at design time.

The clinical paradox crystallized when tirzepatide produced weight loss exceeding semaglutide head-to-head (Frias et al., N Engl J Med 2021, the SURPASS-2 head-to-head Phase 3) and obesity-class weight loss of −22.5% at 72 weeks in the foundational obesity trial (Jastreboff et al. 2022, SURMOUNT-1). The dual-agonist with the GIPR-activating arm outperformed the GLP-1 monoagonist by a margin that the "GIPR antagonism causes weight loss" framing could not accommodate. Two reconciliations followed. The first came from the Helmholtz Munich / Indiana University medicinal-chemistry consortium that originated the unimolecular dual-agonist design strategy: Mroz et al., Mol Metab 2019, 20:51–62 demonstrated that optimized long-acting GIP analogs — engineered for DPP-4 resistance and albumin-binding pharmacokinetics — produced weight loss in diet-induced obese mice through GIP-receptor agonism, that the weight effect was preserved in GLP-1R-knockout mice but abolished in GIPR-knockout mice, and that a fully potent long-acting GIPR antagonist did not lower body weight in the same model. Agonism, not antagonism, drove the obesity phenotype in the optimized-pharmacokinetic setting. The second reconciliation came from receptor pharmacology — Willard et al. 2020 characterized tirzepatide as imbalanced toward GIP-receptor potency and biased at the GLP-1 receptor toward cAMP signaling over β-arrestin recruitment, framing the dual-agonist signal as biased agonism rather than balanced co-stimulation. The implication is that pharmacological GIPR activation under supraphysiological dosing, biased signaling, and chronic receptor occupancy produces a tissue-specific effect profile that does not recapitulate the physiological GIP biology characterized in the rodent-knockout era. Possible mechanistic contributors include desensitization-and-functional-antagonism dynamics at the GIPR in adipose tissue, central appetite-circuit engagement through hypothalamic GIPR populations, and synergy with concurrent GLP-1-receptor activation that the physiological-GIP literature could not model.

The applied implication runs through the tirzepatide-versus-semaglutide weight-loss differential. In SURMOUNT-1, the 15-mg tirzepatide arm reached −22.5% body weight at 72 weeks; in STEP 1, the 2.4-mg semaglutide arm reached −14.9% at 68 weeks. The roughly 7-point treatment-difference advantage is the editorial center of why the dual-agonist class is the new metabolic frontier rather than an incremental refinement on GLP-1 monoagonism. How much of that advantage is attributable to the GIP arm specifically — as opposed to differences in GLP-1-receptor partial agonism, biased signaling, or dosing intensity — is the active mechanistic question. The Perez-Tilve 2026 BWB3054 paper extended the dissection further by demonstrating that a GIPR:GCGR co-agonist with >100-fold attenuated GLP-1R activity matched retatrutide's weight effect in diet-induced obese mice — including in GLP-1R-knockout animals — re-framing the GIP and glucagon arms as carrying a substantial share of the obesity load independent of GLP-1R signaling.

The class context across the corpus follows the same receptor-engagement breadth story. The GLP-1 receptor pharmacology dossier walks the monoagonist → dual-incretin → triple-agonist progression; the peptide receptor pharmacology atlas covers the broader class B GPCR landscape; the fat-loss decision guide addresses applied positioning. The GIP-receptor arm currently belongs exclusively to tirzepatide among approved drugs and retatrutide among late-stage candidates — the adjacent dual-agonist class composed of mazdutide, survodutide, and pemvidutide pairs GLP-1 with glucagon-receptor agonism and skips the GIP arm, while cagrilintide operates outside the incretin axis entirely on the amylin receptor.

The honest framing has three parts. First, native GIP is not a drug — it is the parent hormone whose receptor is the pharmacological target, and the molecules acting on that receptor in human medicine are engineered analogs rather than the native sequence. Second, the historical "GIP makes you fat" framing is not wrong about physiological GIP biology — adipose lipid storage is a real GIPR effect — but the reconciliation with the clinical pharmacology runs through the difference between physiological and supraphysiological dosing, biased agonism, and tissue-specific receptor dynamics the early knockout literature could not model. Third, the relative arm contributions inside tirzepatide and retatrutide remain partially open questions; the receptor-pharmacology, preclinical-knockout, and emerging GIPR-only programs are collectively the ongoing experimental dissection, and no GIP-receptor-only agonist has yet reached clinical approval.